Treatment of depression with antiglucocorticoid drugs

Psychosomatic Medicine

Volumn 61, Issue 5, 1999, Pages 698-711

  Wolkowitz, Owen M ^a   Reus, Victor I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressant; Antiglucocorticoid; Cortisol; Cushing's disease; Cushing's syndrome; Depression

Indexed keywords

CORTICOSTEROID; HYDROCORTISONE;

ARTICLE; CLINICAL TRIAL; CUSHING DISEASE; CUSHING SYNDROME; DEPRESSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; META ANALYSIS; OBSESSION; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0032868082     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006842-199909000-00011     Document Type: Article

References (160)

1. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James NM, Kronfol Z, Lohr N, Steiner M, deVinge JP, Young E: A specific laboratory test for the diagnosis of melancholia. Arch Gen Psychiatry 1981;38:15-22.
2. Reus VI: Toward an understanding of cortisol dysregulation in major depression: a review of studies of the dexamethasone suppression test and urinary free-cortisol. Psychiatr Med 1985;3:1-21.
3. Murphy BE: Steroids and depression. J Steroid Biochem Mol Biol 1991;38:537-59.
4. Nelson JC, Davis JM: DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997;154:1497-503.
5. Pepper GM, Krieger DT: Hypothalamic-pituitary-adrenal abnormalities in depression: their possible relation to central mechanisms regulating ACTH release. In: Post RM, Ballenger JC, editors. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1984. p. 245-270.
6. Gold PW, Chrousos GP: Clinical studies with corticotropin releasing factor: implications for the diagnosis and pathophysiology of depression, Cushing's disease, and adrenal insufficiency. Psychoneuroendocrinology 1985;10:401-419.
7. Nemeroff CB: The role of corticotropin-releasing factor in the pathogenesis of major depression. Pharmacopsychiatry 1988;21:76-82.
8. Dinan TG: Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction? J Clin Psychiatry 1996;57:14-8.
9. McEwen BS, Davis PG, Parsons B, Pfaff DW: The brain as target for steroid hormone action. Annu Rev Neurosci 1979;2:65-112.
10. McEwen BS, Angulo J, Cameron H, Chao HM: Paradoxical effects of adrenal steroids on the brain: protection versus degeneration. Biol Psychiatry 1992;31:177-199.
11. Wolkowitz OM: Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology 1994;19:233-55.
12. Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM, Nemeroff CB: Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci USA 1996;93:1619-23.
13. Sapolsky RM: Stress, glucocorticoids, and damage to the nervous system: the current state of confusion. Stress 1996;1:1-19.
14. O'Brien JT: The "glucocorticoid cascade" hypothesis in man. Br J Psychiatry 1997;170:199-201.
15. Porter NM, Landfield PW: Stress hormones and brain aging: adding injury to insult? Nat Neurosci 1998;1:3-4.
16. Quarton GC, Clark LD, Cobb S, Bauer W: Mental disturbances associated with ACTH and cortisone: a review of explanatory hypotheses. Medicine 1955;34:13-50.
17. Fawcett JA, Bunney WE Jr: Pituitary adrenal function and depression: an outline for research. Arch Gen Psychiatry 1967;16:517-35.
18. Rubin RT, Mandell AJ: Adrenal cortical activity in pathological emotional states: a review. Am J Psychiatry 1966;123:387-400.
19. Reus VI: Pituitary-adrenal disinhibition as the independent variable in the assessment of behavioral symptoms. Biol Psychiatry 1982;17:317-325.
20. Reus VI: Hormonal mediation of the memory disorder in depression. Drug Dev Res 1984;4:489-500.
21. Reus VI, Peeke HV, Miner C: Habituation and cortisol dysregulation in depression. Biol Psychiatry 1985;20:980-9.
22. Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO: A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 1985;19:57-64.
23. Kathol RG: Etiologic implications of corticosteroid changes in affective disorder. Psychiatr Med 1985;3:135-62.
24. McEwen BS: Glucocorticoid-biogenic amine interactions in relation to mood and behavior. Biochem Pharmacol 1987;36:1755-63.
25. Starkman MN, Schteingart DE, Schork MA: Cushing's syndrome after treatment: changes in cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Res 1986;19:177-88.
26. Dubrovsky B: Adrenal steroids and the physiopathology of a subset of depressive disorders. Med Hypotheses 1991;36:300-5.
27. Checkley S: Neuroendocrine mechanisms and the precipitation of depression by life events. Br J Psychiatry Suppl 1992;15:7-17.
28. Murphy BEP, Wolkowitz OM: The pathophysiologic significance of hypercorticism: antiglucocorticoid strategies. Psychiatr Ann 1993;23:682-690.
29. Veldhuis HD, De Korte CC, De Kloet ER: Glucocorticoids facilitate the retention of acquired immobility during forced swimming. Eur J Pharmacol 1985;115:211-7.
30. Sandi C, Borrell J, Guaza C: Behavioral, neuroendocrine, and immunological outcomes of escapable or inescapable shocks. Physiol Behav 1992;51:651-6.
31. Kennett GA, Dickinson SL, Curzon G: Central serotonergic responses and behavioural adaptation to repeated immobilisation: the effect of the corticosterone synthesis inhibitor metyrapone. Eur J Pharmacol 1985;119:143-52.
32. Nankai M, Yamada S, Muneoka K, Toru M: Increased 5-HT2 receptor-mediated behavior 11 days after shock in learned helplessness rats. Eur J Pharmacol 1995;281:123-30.
33. Barden N: Regulation of corticosteroid receptor gene expression in depression and antidepressant action. J Psychiatry Neurosci 1999;24:25-39.
34. Papolos DF, Edwards E, Marmur R, Lachman HM, Henn FA: Effects of the antiglucocorticoid RU 38486 on the induction of learned helpless behavior in Sprague-Dawley rats. Brain Res 1993;615:304-9.
35. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M: Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998;19:269-301.
36. Xu L, Holscher C, Anwyl R, Rowan MJ: Glucocorticoid receptor and protein/RNA synthesis-dependent mechanisms underlie the control of synaptic plasticity by stress. Proc Natl Acad Sci USA 1998;95:3204-8.
37. Biegon A: Effects of steroid hormones on the serotonergic system. Ann NY Acad Sci 1990;600:427-32.
38. Chauloff F: Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res Rev 1993;18:1-32.
39. Curzon G: Effects of stress on 5-HT function. Neuropsychopharmacology 1994;10(suppl3, part 1):928S.
40. Slotkin TA, McCook EC, Ritchie JC, Seidler FJ: Do glucocorticoids contribute to the abnormalities in serotonin transporter expression and function seen in depression? An animal model. Biol Psychiatry 1996;40:576-84.
41. Price LH, Cappiello A, Malison RT, McDougle CJ, Pelton GH, Schollnhammer G, Heninger GR: Effects of antiglucocorticoid treatment on 5-HT1A function in depressed patients and healthy subjects. Neuropsycopharmacology 1997;17:246-257.
42. Lopez JF, Chalmers DT, Little KY, Watson SJ: Regulation of serotoninlA, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998;43:547-73.
43. Wolkowitz OM, Rubinow D, Doran AR, Breier A, Berrettini WH, Kling MA, Pickar D: Prednisone effects on neurochemistry and behavior: preliminary findings. Arch Gen Psychiatry 1990;47:963-8.
44. Lesch KP, Lerer B: The 5-HT receptor-G-protein-effector system complex in depression. I. Effect of glucocorticoids. J Neural Transm Gen Sect 1991;84:3-18.
45. Wolkowitz OM, Rubinow DR, Breier A, Doran AR, Davis C, Pickar D: Prednisone decreases CSF somatostatin in healthy humans: implications for neuropsychiatric illness. Life Sci 1987;41:1929-33.
46. Holsboer F, Barden N: Antidepressants and hypothalamicpituitary-adrenocortical regulation. Endocr Rev 1996;17:187-205.
47. Maes M, Meltzer HY: The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995. p. 933-944.
48. Mendelson SD, McEwen BS: Autoradiographic analyses of the effects of adrenalectomy and corticosterone on 5-HT1A and 5-HT1B receptors in the dorsal hippocampus and cortex of the rat. Neuroendocrinology 1992;55:444-50.
49. Abrahamsen GC, Kandawire MJ, Carr KD: Aminoglutethimide, a corticosteroid synthesis inhibitor, facilitates brain stimulation reward in food-restricted rats: an investigation of underlying mechanisms. Psychopharmacology (Berl) 1997;133:405-12.
50. Roozendaal B, Bohus B, McGaugh JL: Dose-dependent suppression of adrenocortical activity with metyrapone: effects on emotion and memory. Psychoneuroendocrinology 1996;21:681-93.
51. Hall ED: Glucocorticoid effects on central nervous excitability and synaptic transmission. Int Rev Neurobiol 1982;23:165-95.
52. Majewska-MD: Steroids and brain activity: essential dialogue between body and mind. Biochem Pharmacol 1987;36:3781-8.
53. Starkman MN: Commentary. Integr Psychiatry 1987;5:258-273.
54. Zakon HH: The effects of steroid hormones on electrical activity of excitable cells. Trends Neurosci 1998;21:202-7.
55. Sapolsky RM, Krey LC, McEwen BS: The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endoer Rev 1986;7:284-301.
56. Starkman MN: The HPA axis and psychopathology: Cushing's syndrome. Psychiatr Ann 1993;23:691-701.
57. Leverenz JB, Wilkinson CW, Wamble M, Corbin S, Grabber JE, Raskind MA, Peskind ER: Effect of chronic high-dose exogenous cortisol on hippocampal neuronal number in aged non-human primates. J Neurosci 1999;19:2356-61.
58. Cohen SI: Cushing's syndrome: a psychiatric study of 29 patients. Br J Psychiatry 1980;136:120-4.
59. Majewska MD: Neurosteroids: endogenous bimodal modulators of the GABAA receptor: mechanism of action and physiological significance. Prog Neurobiol 1992;38:379-95.
60. Majewska MD: Neuronal actions of dehydroepiandrosterone: possible roles in brain development, aging, memory, and affect. Ann NY Acad Sci 1995;774:111-20.
61. Herbert J, Goodyer IM, Altham PME, Pearson J, Secher SM, Shiers HM: Adrenal secretion and major depression in 8- to 16-year-olds. II. Influence of co-morbidity at presentation. Psychol Med 1996;26:257-263.
62. Herbert J: Stress, the brain, and mental illness. BMJ 1997;315:530-535.
63. Herbert J: Neurosteroids, brain damage, and mental illness. Exp Gerontol 1998;33:713-727.
64. Baulieu EE: Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res 1997;52:1-32.
65. Wolkowitz OM, Kroboth P, Reus VI, Fabian TJ: DHEA in aging and mental health. In: Morrison M, editor. Hormones, aging and mental disorders. Cambridge: Cambridge University Press. In press.
66. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E: Double-blind treatment of major depression with dehydroepiandrosterone (DHEA). Am J Psychiatry 1999;156:646-649.
67. Boston Collaborative Drug Surveillance Program: Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972;13:694-698.
68. Hall RC, Popkin MK, Stickney SK, Gardner ER: Presentation of the steroid psychoses. J Nerv Ment Dis 1979;167:229-36.
69. Ling MH, Perry PJ, Tsuang MT: Side effects of corticosteroid therapy: psychiatric aspects. Arch Gen Psychiatry 1981;38:471-7.
70. Pies R: Differential diagnosis and treatment of steroid-induced affective syndromes. Gen Hosp Psychiatry 1995;17:353-61.
71. Reus VI, Wolkowitz OM: Behavioral effects of corticosteroid therapy. Psychiatr Ann 1993;23:703-708.
72. Naber D, Sand P, Heigl B: Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment: a prospective study. Psychoneuroendocrinology 1996;21:25-31.
73. Wolkowitz OM, Reus VI, Canick J, Levin B, Lupien S: Glucocorticoid medication, memory and steroid psychosis in medical illness. Ann NY Acad Sci 1997;823:81-96.
74. Plihal W, Krug R, Pietrowsky R, Fehm HL, Born J: Corticosteroid receptor mediated effects on mood in humans. Psychoneuroendocrinology 1996;21:515-23.
75. Starkman MN, Schteingart DE, Schork MA: Depressed mood and other psychiatric manifestations of Cushing's syndrome: relationship to hormone levels. Psychosom Med 1981;43:3-18.
76. Whelan TB, Schteingart DE, Starkman MN, Smith A: Neuropsychological deficits in Cushing's syndrome. J Nerv Ment Dis 1980;168:753-7.
77. Trethowen WH, Cobb W: Neuropsychiatric aspects of Cushing's syndrome. Arch Neurol Psychiatr 1952:67:283-309.
78. Haskett RF: Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry 1985;142:911-6.
79. Kling MA, Roy A, Doran AR, Calabrese JR, Rubinow DR, Whitfield HJ Jr, May C, Post RM, Chrousos GP, Gold PW: Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications. J Clin Endocrinol Metab 1991;72:260-71.
80. Loosen PT, Chambliss B, DeBold CR, Shelton R, Orth DN: Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry 1992;25:192-8.
81. Sonino N, Fava GA, Belluardo P, Girelli ME, Boscaro M: Course of depression in Cushing's syndrome: response to treatment and comparison with Graves' disease. Horm Res 1993;39:202-6.
82. Kelly WF, Checkley SA, Bender DA: Cushing's syndrome, tryptophan and depression. Br J Psychiatry 1980;136:125-32.
83. Kelly WF, Checkley SA, Bender DA, Mashiter K: Cushing's syndrome and depression - a prospective study of 26 patients. Br J Psychiatry 1983;142:16-9.
84. Hamm FC: Adrenal surgery for psychosis associated with Cushing's syndrome. Arch Surg 1955;71:617-619.
85. Taft P, Martin FIR, Melick R: Cushing's syndrome - a review of the response to treatment of 42 patients. Aust Ann Med 1970;4:295-303.
86. Gifford S, Gunderson JG: Cushing's disease as a psychosomatic disorder: a selective review of the clinical and experimental literature and a report of ten cases. Perspect Biol Med 1970;13:169-221.
87. Welbourn RB, Montgomery DAD, Kennedy TL: The natural history of treated Cushing's syndrome. Br J Surg 1971;58:1-16.
88. Regestein QR, Rose LI, Williams GH: Psychopathology in Cushing's syndrome. Arch Intern Med 1972;130:114-117.
89. Kelly WF, Barnes AJ, Cassar J, White M, Mashiter K, Loizou S, Welbourn RB, Joplin GF: Cushing's syndrome due to adrenocortical carcinoma - a comprehensive clinical and biochemical study of patients treated by surgery and chemotherapy. Acta Endocrinol 1979;91:303-318.
90. Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM: Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Q J Med 1979;48:465-72.
91. Angeli A, Frairia R: Ketoconazole therapy in Cushing's disease [letter]. Lancet 1985;1:821.
92. Kramlinger KG, Peterson GC, Watson PK, Leonard LL: Metyrapone for depression and delirium secondary to Cushing's syndrome. Psychosomatics 1985;26:67, 71.
93. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL: Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985;61:536-40.
94. Voigt KH, Bossert S, Bretschneider S, Bliestle A, Fehm HL: Disturbed cortisol secretion in man: contrasting Cushing's syndrome and endogenous depression. Psychiatry Res 1985;15:341-350.
95. Sonino N, Boscaro M, Ambroso G, Merola G, Mantero F: Prolonged treatment of Cushing's disease with metyrapone and aminoglutethimide. IRCS Med Sci 1986;14:485-486.
96. Loli P, Berselli ME, Tagliaferri M: Use of ketoconazole in the treatment of Cushing's syndrome. J Clin Endocrinol Metab 1986;63:1365-1371.
97. Ravaris CL, Sateia MJ, Beroza KW, Noordsy DL, Brinck-Johnsen T: Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman [letter]. Arch Gen Psychiatry 1988;45:966-7.
98. Ravaris CL, Brinck-Johnsen T, Elliott B: Clinical use of ketoconazole in hypercortisoluric depressives. Biol Psychiatry 1994;35:679.
99. Arteaga E, Mahana D, Gonzalez R, Martinez P: Cushing syndrome caused by macronodular adrenal hyperplasia, independent of ACTH: report of a case [in Spanish]. Rev Med Chil 1989;117:1398-402.
100. Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D: Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 1991;35:347-52.
101. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA, Besser GM: Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991;35:169-78.
102. Kelly WF, Kelly MJ, Faragher B: A prospective study of psychiatric and psychological aspects of Cushing's syndrome. Clin Endocrinol 1996;45:715-72.
103. Li KL, Tung SC, Wang PW: The effect of ketoconazole in pre-operative treatment in Cushing's syndrome: three cases report. Chang Keng I Hsueh 1996;19:358-63.
104. Mauri M, Sinforiani E, Bono G, Vignati F, Berselli ME, Attanasio R, Nappi G: Memory impairment in Cushing's disease. Acta Neurol Scand 1993;87:52-5.
105. van der Lely AJ, Foeken K, van der Mast RC, Lamberts SW: Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med 1991;114:143-4.
106. Zeiger MA, Fraker DL, Pass HI, Nieman LK, Cutler GB Jr, Chrousos GP, Norton JA: Effective reversibility of the signs and symptoms of hypercortisolism by bilateral adrenalectomy. Surgery 1993;114:1138-43.
107. Leigh H, Kramer SI: The psychiatric manifestations of endocrine disease. Adv Intern Med 1984;29:413-45.
108. Winokur G, Black DW, Nasrallah A: DST nonsuppressor status: relationship to specific aspects of the depressive syndrome. Biol Psychiatry 1987;22:360-8.
109. Meador-Woodruff JH, Greden JF, Grunhaus L, Haskett RF: Severity of depression and hypothalamic-pituitary-adrenal axis dysregulation: identification of contributing factors. Acta Psychiatr Scand 1990;81:364-71.
110. Wolkowitz OM, Reus VI, Manfred IF, Chan T, Canick J, Ormiston S, Ingbar J, Brizendine L: Antiglucocorticoid medication effects on specific depressive symptoms. Biol Psychiatry 1994;35:678.
111. Greden JF, Gardner R, King D, Grunhaus L, Carroll BJ, Kronfol Z: Dexamethasone suppression tests in antidepressant treatment of melancholia: the process of normalization and testretest reproducibility. Arch Gen Psychiatry 1983;40:493-500.
112. Goodyer IM, Herbert J, Altham PME: Evening cortisol/DHEA ratio predicts persistent major depression in school age children and adolescents. Psychol Med. In press
113. Ribeiro SC, Tandon R, Grunhaus L, Greden JF: The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993;150:1618-29.
114. Rothschild AJ, Samson JA, Bond TC, Luciana MM, Schildkraut JJ, Schatzberg AF: Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression. Biol Psychiatry 1993;34:392-400.
115. Amsterdam JD, Maislin G, Gold P, Winokur A: The assessment of abnormalities in hormonal responsiveness at multiple levels of the hypothalamic-pituitary-adrenocortical axis in depressive illness. Psychoneuroendocrinology 1989:14:43-62.
116. Schulkin J, McEwen BS, Gold PW: Allostasis, amygdala, and anticipatory angst. Neurosci Biobehav Rev 1994;18:385-96.
117. Checkley AS, O'Dwyer AM, Raven P, Taylor N, Lightman S: Antidepressant effects of treatments with metyrapone and hydrocortisone. Biol Psychiatry 1994;35:711.
118. Pepin MC, Pothier F, Barden N: Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol Pharmacol 1992;42:991-995.
119. Heuser I, Schweiger U, Gotthardt U, Schmider J, Lammers C-H, Dettling M, Yassouridis A, Holsboer F: Pituitary-adrenalsystem regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 1996;153:93-99.
120. Reus VI, Wolkowitz OM, Frederick S: Antiglucocorticoid treatments in psychiatry. Psychoneuroendocrinology 1997;22:S121-4.
121. Murphy BEP: Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 1997;22(Suppl 1):S125-132.
122. Murphy BE, Ghadirian AM, Dhar V: Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy. Can J Psychiatry 1998;43:279-86.
123. Ghadirian AM, Englesmann F, Dhar V, Filipini D, Keller R, Chouinard G, Murphy BEP: The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 1995;37:369-375.
124. Wolkowitz OM, Reus VI, Manfredi F, Ingbar J, Brizendine L, Weingartner H: Ketoconazole treatment of hypercortisolemic depression. Am J Psychiatry 1993;150:810-812.
125. Amsterdam J, Mosley PD, Rosenzweig M: Assessment of adrenocortical activity in refractory depression: steroid suppression with ketoconazole. In: Nolan W, Zohar J, Roose S, Amsterdam J, editors. Refractory depression. Chichester: John Wiley, 1994. p. 199-210.
126. Anand A, Malison R, McDougle CJ, Price LH: Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report. Biol Psychiatry 1995;37:338-340.
127. O'Dwyer AM, Lightman SL, Marks MN, Checkley SA: Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord 1995;33:123-128.
128. Raven PW, O'Dwyer AM, Taylor NF, Checkley SA: The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles. Psychoneuroendocrinology 1996;21:277-286.
129. Sovner R, Fogelman S: Ketoconazole therapy for atypical depression. J Clin Psychiatry 1996;57:227-228.
130. Thakore JH, Dinan T: Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 1995;37:364-368.
131. Iizuka H, Kishimotor A, Nakamura J, Mizukawa R: Clinical effects of cortisol synthesis inhibition on treatment-resistant depression [in Japanese]. Nihon Shinkei Seishin Yakurigaku Zasshi 1996;16:33-36.
132. Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R, Canick J: Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry 1999;45:1070-1074.
133. Murphy BE, Filipini D, Ghadirian AM: Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993;18:209-13.
134. Murphy BE, Dhar V, Ghadirian AM, Chouinard G, Keller R: Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol 1991;11:121-6.
135. Murphy BE: Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Mol Biol 1991;39:239-44.
136. Chouinard G, Belanger MC, Beauclair L, Sultan S, Murphy BE: Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: a case report. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:1067-79.
137. Beale MD, Arana GW: Dexamethasone for treatment of major depression in patients with bipolar disorder [letter]. Am J Psychiatry 1995;152:959-60.
138. Arana GW, Santos AB, Laraia MT, McLeod-Bryant S, Beale MD, Rames LJ, Roberts JM, Dias JK, Molloy M: Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am J Psychiatry 1995;152:265-7.
139. Arana GW: Intravenous dexamethasone for symptoms of major depressive disorder [letter]. Am J Psychiatry 1991;148:1401-2.
140. Arana GW, Forbes RA: Dexamethasone for the treatment of depression: a preliminary report. J Clin Psychiatry 1991;52:304-6.
141. Dinan TG, Lavelle E, Cooney J, Burnett F, Scott L, Dash A, Thakore J, Berti C: Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand 1997;95:58-61.
142. Goodwin GM, Muir WJ, Seckl JR, Bennie J, Carroll S, Dick H, Fink G: The effects of cortisol infusion upon hormone secretion from the anterior pituitary and subjective mood in depressive illness and in controls. J Affect Disord 1992;26:73-83.
143. Wolkowitz OM, Reus VI, Manfredi F, Chan T, Ormiston S, Johnson R: Dexamethasone for depression [letter]. Am J Psychiatry 1996;153:1112.
144. De Kloet ER: Why dexamethasone poorly penetrates in brain. Stress 1997;2:13-20.
145. Barden N, Reul JM, Holsboer F: Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 1995;18:6-11.
146. Stricker BH, Blok APR, Bronkhorst FB, Van Parys GE, Desmet VJ: Ketoconazole-associated hepatic injury. J Hepatol 1986;3:399-406.
147. Tabor E: Hepatotoxicity of ketoconazole in men and in patients under 50. N Engl J Med 1987;316:1606-7.
148. Barletta D, Gasperi M, Materazzi F, Pucci E, Luisi M: Effects of ketoconazole treatment on ITT induced ACTH-adrenal secretion. J Endocrinol Invest 1988;11:731.
149. Berselli ME, Tagliaferri M, Vignati F, Loli P: Effect of ketoconazole on CRH-induced ACTH and cortisol release in patients with Cushing's disease. Horm Metab Res 1987;16(Suppl):58-59.
150. Best TR, Jenkins JK, Murphy FY, Nicks SA, Bussell KL, Vesely DL: Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. Am J Med 1987;82:676-680.
151. DeCoster R, Caers I, Coene MC, Amery W, Beerens D, Haelterman C: Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients. Clin Endocrinol 1986;24:657-664.
152. Feldman D: Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev 1986;7:409-420.
153. Lake-Bakaar G, Scheuer PJ, Sherlock S: Hepatic reactions associated with ketoconazole in the United Kingdom. BMJ 1987;294:412-422.
154. McCance DR, Ritchie CM, Sheridan B, Atkinson AB: Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet 1987;1:573.
155. Miller WL, Tyrrell JB: The adrenal cortex. In: Felig P, Baxter JD, Frohman LA, editors. Endocrinology and metabolism. New York: McGraw Hill, 1995. p. 555-712.
156. Orth DN, Kovacs WJ, DeBold CR: The adrenal cortex. In: Wilson ID, Foster DW, editors. Williams textbook of endocrinology. Philadelphia: WB Saunders; 1992. p. 489-620.
157. Loose DS, Stover EP, Feldman D: Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. J Clin Invest 1983;72:404-408.
158. Stalla GK, Stalla J, von Werder K, Muller OA, Gerzer R, Hollt V, Jakobs KH: Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology 1989;125:699-706.
159. Sonino N: The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987;317:812-818.
160. Spillane JD: Nervous and mental disorders in Cushing's syndrome. Brain 1951;74:72-94.